AU2008343843A1 - Improved medical devices - Google Patents

Improved medical devices Download PDF

Info

Publication number
AU2008343843A1
AU2008343843A1 AU2008343843A AU2008343843A AU2008343843A1 AU 2008343843 A1 AU2008343843 A1 AU 2008343843A1 AU 2008343843 A AU2008343843 A AU 2008343843A AU 2008343843 A AU2008343843 A AU 2008343843A AU 2008343843 A1 AU2008343843 A1 AU 2008343843A1
Authority
AU
Australia
Prior art keywords
connexin
medical device
agent
agents
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008343843A
Other languages
English (en)
Inventor
David L. Becker
Bradford J. Duft
Colin R. Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
CoDa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CoDa Therapeutics Inc filed Critical CoDa Therapeutics Inc
Publication of AU2008343843A1 publication Critical patent/AU2008343843A1/en
Priority to AU2015200114A priority Critical patent/AU2015200114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Prostheses (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
AU2008343843A 2007-12-21 2008-12-22 Improved medical devices Abandoned AU2008343843A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015200114A AU2015200114A1 (en) 2007-12-21 2015-01-12 Improved medical devices

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US873807P 2007-12-21 2007-12-21
US61/008,738 2007-12-21
PCT/US2008/014023 WO2009085272A2 (en) 2007-12-21 2008-12-22 Improved medical devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015200114A Division AU2015200114A1 (en) 2007-12-21 2015-01-12 Improved medical devices

Publications (1)

Publication Number Publication Date
AU2008343843A1 true AU2008343843A1 (en) 2009-07-09

Family

ID=40466841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008343843A Abandoned AU2008343843A1 (en) 2007-12-21 2008-12-22 Improved medical devices

Country Status (6)

Country Link
US (4) US9035037B2 (https=)
EP (1) EP2234656A2 (https=)
JP (4) JP2011507599A (https=)
AU (1) AU2008343843A1 (https=)
CA (1) CA2710386A1 (https=)
WO (1) WO2009085272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073629B1 (ko) 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
DK2819682T3 (en) * 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
CN105498074B (zh) * 2015-12-25 2017-08-08 李雷 血管壁修复系统
WO2017190152A1 (en) * 2016-04-29 2017-11-02 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
RU2636418C1 (ru) * 2017-03-16 2017-11-23 Дмитрий Викторович Давыдов Способ коррекции экзофтальма и имплантат для увеличения объема орбиты в области сформированного костного дефекта при коррекции экзофтальма
CA3061738A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
WO2019152917A1 (en) 2018-02-02 2019-08-08 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
WO2023219655A1 (en) * 2022-05-13 2023-11-16 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias
US20240299440A1 (en) * 2023-03-07 2024-09-12 Amber Ophthalmics, Inc. Novel treatments for ocular disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5092877A (en) 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US4994071A (en) 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5857998A (en) 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP1486565B1 (en) 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Combination of PDGF, KGF, IGF, and IGFBP for wound healing
EP1806131A3 (en) 1996-07-22 2007-08-01 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6855505B2 (en) 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
EP1591128A1 (en) 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
DE19902481A1 (de) * 1999-01-22 2000-07-27 Signus Medizintechnik Gmbh Wirbelsäulenersatzkörper
EP2314321B1 (en) * 1999-01-27 2014-06-04 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins
GB9903598D0 (en) 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
CN1638790A (zh) 2002-01-29 2005-07-13 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
KR101350837B1 (ko) * 2003-12-03 2014-01-14 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
WO2006084005A2 (en) * 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
KR102073629B1 (ko) * 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
EP2245158A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Also Published As

Publication number Publication date
WO2009085272A3 (en) 2010-07-29
WO2009085272A9 (en) 2010-06-10
CA2710386A1 (en) 2009-07-09
US20170189469A1 (en) 2017-07-06
JP2017064431A (ja) 2017-04-06
EP2234656A2 (en) 2010-10-06
JP2015006440A (ja) 2015-01-15
US9035037B2 (en) 2015-05-19
US20110166653A1 (en) 2011-07-07
US10251929B2 (en) 2019-04-09
US20150297804A1 (en) 2015-10-22
JP2018198954A (ja) 2018-12-20
US9561311B2 (en) 2017-02-07
US20190290719A1 (en) 2019-09-26
WO2009085272A2 (en) 2009-07-09
JP2011507599A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
US10251929B2 (en) Medical devices
Junge et al. Mesh biocompatibility: effects of cellular inflammation and tissue remodelling
JP3803857B2 (ja) 活性剤の制御された送達のためのポリマーコーティング
JP2007535368A (ja) 埋め込み型用具上のコーティングの熱特性及び機械的特性を調節する方法
JP2009523489A (ja) 被覆医療用具及びその製造方法
JP2004537344A (ja) 医療装置
US20080215137A1 (en) Therapeutic driving layer for a medical device
US20110245184A1 (en) Treatment of surgical adhesions
CA2562018A1 (en) Bioactive stents for type ii diabetics and methods for use thereof
EP2532373A1 (en) Biocompatible device
AU2008343756A1 (en) Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
EP2237786A2 (en) Use of inhibitors of connexin43 for treatment of fibrotic conditions
US20160158420A1 (en) Coatings formed from stimulus-sensitive material
JP2015013880A (ja) 外科的癒着の治療のための抗コネキシンポリヌクレオチドの使用
AU2015200114A1 (en) Improved medical devices
WO2006020231A2 (en) Medical devices and methods for reducing localized fibrosis
JP2006503605A (ja) 医療装置
Boomker et al. The modulation of angiogenesis in the foreign body response by the poxviral protein M-T7
US20080234657A1 (en) Methods for contributing to cardiovascular treatments
Malhotra Improving Matters of the Heart: The Use of Select Pharmaceutical Polymers in Cardiovascular Intervention
AU2017200710A1 (en) Treatment of fibrotic conditions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted